Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial. — Stella
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
(3 sites) China
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Dongguan Taixin Hospital, Dongguan, Guang Shanghai YaKe Biotechnology Ltd., Shanghai, Shanghai Municipality
Key details Phase
Early testing / Safety & dosing
Sponsor
Sun Yat-Sen University Cancer Center
Collaborators
Yake Biotechnology Ltd., Dongguan Taixin Hospital
Enrollment target
~10 participants
Primary completion
December 2027
Age range
1 Year – 50 Years
Last updated February 2025